Clinics in Dermatology
Volume 27, Issue 5 , Pages 485-494 , September 2009

Cosmeceuticals and peptides

References 

  1. Pierard GE. EEMCO guidance to the in vivo assessment of tensile functional properties of the skin. Part 1: relevance to the structures and ageing of the skin and subcutaneous tissues. Skin Pharmacol Appl Skin Physiol. 1999;12:352–362
  2. Woodley DT, O'Keefe EJ, Prunieras M. Cutaneous wound healing: a model for cell-matrix interactions. J Am Acad Dermatol. 1985;12:420–433
  3. Adams JC, Watt FM. Regulation of development and differentiation by the extracellular matrix. Development. 1993;117:1183–1198
  4. Smith LT, Holbrook KA, Madri JA. Collagen types I, III, and V in human embryonic and fetal skin. Am J Anat. 1986;175:507–521
  5. Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol. 2004;49:199–202
  6. Labat-Robert J. Cryptic sites and matrikines: cellular effects of fibronectin and laminin peptides. J Soc Biol. 2003;197:45–51
  7. Tran KT, Lamb P, Deng JS. Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci. 2005;40:11–20
  8. Swindle CS, Tran KT, Johnson TD, et al. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol. 2001;154:459–468
  9. Pirila E, Sharabi A, Salo T, et al. Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun. 2003;303:1012–1017
  10. Hornebeck W, Maquart FX. Role of matrikins in melanoma progression. Ann Pharm Fr. 2006;64:83–86
  11. Tran KT, Griffith L, Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen. 2004;12:262–268
  12. Aycock RS, Raghow R, Stricklin GP, Seyer JM, Kang AH. Post-transcriptional inhibition of collagen and fibronectin synthesis by a synthetic homolog of a portion of the carboxyl-terminal propeptide of human type I collagen. J Biol Chem. 1986;261:14355–14360
  13. Katayama K, Seyer JM, Raghow R, Kang AH. Regulation of extracellular matrix production by chemically synthesized subfragments of type I collagen carboxy propeptide. Biochemistry. 1991;30:7097–7104
  14. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. Apentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268:9941–9944
  15. Price LS, Roos PJ, Shively VP, Sandberg LB. Valyl-alanyl-prolyl-glycine (VAPG) serves as a quantitative marker for human elastins. Matrix. 1993;13:307–311
  16. Grosso LE, Scott M. PGAIPG, a repeated hexapeptide of bovine tropoelastin, is a ligand for the 67-kDa bovine elastin receptor. Matrix. 1993;13:157–164
  17. Sandberg LB, Wolt TB, Leslie JG. Quantitation of elastin through measurement of its pentapeptide content. Biochem Biophys Res Commun. 1986;136:672–678
  18. Duca L, Floquet N, Alix AJ, Haye B, Debelle L. Elastin as a matrikine. Crit Rev Oncol Hematol. 2004;49:235–244
  19. Kunitomo M, Jay M. Elastin fragment-induced monocyte chemotaxis. The role of desmosines. Inflammation. 1985;9:183–188
  20. Fulop T, Jacob MP, Varga Z, Foris G, Leovey A, Robert L. Effect of elastin peptides on human monocytes: Ca2+ mobilization, stimulation of respiratory burst and enzyme secretion. Biochem Biophys Res Commun. 1986;141:92–98
  21. Senior RM, Griffin GL, Mecham RP, Wrenn DS, Prasad KU, Urry DW. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J Cell Biol. 1984;99:870–874
  22. Uemura Y, Okamoto K. Elastin-derived peptide induces monocyte chemotaxis by increasing intracellular cyclic GMP level and activating cyclic GMP dependent protein kinase. Biochem Mol Biol Int. 1997;41:57–64
  23. Hornebeck W, Robinet A, Duca L, Antonicelli F, Wallach J, Bellon G. The elastin connection and melanoma progression. Anticancer Res. 2005;25:2617–2625
  24. Long MM, King VJ, Prasad KU, Freeman BA, Urry DW. Elastin repeat peptides as chemoattractants for bovine aortic endothelial cells. J Cell Physiol. 1989;140:512–518
  25. Blood CH, Sasse J, Brodt P, Zetter BR. Identification of a tumor cell receptor for VGVAPG, an elastin-derived chemotactic peptide. J Cell Biol. 1988;107:1987–1993
  26. Blood CH, Zetter BR. Membrane-bound protein kinase C modulates receptor affinity and chemotactic responsiveness of Lewis lung carcinoma sublines to an elastin-derived peptide. J Biol Chem. 1989;264:10614–10620
  27. Robinet A, Fahem A, Cauchard JH, et al. Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci. 2005;118:343–356
  28. Kamoun A, Landeau JM, Godeau G, et al. Growth stimulation of human skin fibroblasts by elastin-derived peptides. Cell Adhes Commun. 1995;3:273–281
  29. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243:85–87
  30. Pickart L, Thayer L, Thaler MM. Asynthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. Biochem Biophys Res Commun. 1973;54:562–566
  31. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238:343–346
  32. Arul V, Gopinath D, Gomathi K, Jayakumar R. Biotinylated GHK peptide incorporated collagenous matrix: A novel biomaterial for dermal wound healing in rats. J Biomed Mater Res B Appl Biomater. 2005;73:383–391
  33. Arul V, Kartha R, Jayakumar R. Atherapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sci. 2007;80:275–284
  34. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92:2368–2376
  35. Pickart L, Thaler MM. Growth-modulating human plasma tripeptide: relationship between molecular structure and DNA synthesis in hepatoma cells. FEBS Lett. 1979;104:119–122
  36. Pickart L, Thaler MM. Growth-modulating tripeptide (glycylhistidyllysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol. 1980;102:129–139
  37. Poole TJ, Zetter BR. Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. Cancer Res. 1983;43:5857–5861
  38. Zetter BR, Rasmussen N, Brown L. An in vivo assay for chemoattractant activity. Lab Invest. 1985;53:362–368
  39. Grosse G, Lindner G. Experimental influence of pharmacological agents on the regeneration of nervous tissue in vitro. Folia Morphol (Praha). 1980;28:345–347
  40. Raju KS, Alessandri G, Ziche M, Gullino PM. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst. 1982;69:1183–1188
  41. Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol. 1994;125:929–943
  42. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51:1049–1056
  43. Pickart L, Lovejoy S. Biological activity of human plasma copper-binding growth factor glycyl-L-histidyl-L-lysine. Methods Enzymol. 1987;147:314–328
  44. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2:259–269
  45. Simeon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67:2257–2265
  46. Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother. 2006;7:653–663
  47. Braff MH, Gallo RL. Antimicrobial peptides: an essential component of the skin defensive barrier. Curr Top Microbiol Immunol. 2006;306:91–110
  48. Harder J, Schroder JM. Antimicrobial peptides in human skin. Chem Immunol Allergy. 2005;86:22–41
  49. Braff MH, Hawkins MA, Di Nardo A, et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol. 2005;174:4271–4278
  50. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J Immunol. 2005;174:6257–6265
  51. Shaykhiev R, Beisswenger C, Kandler K, et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol. 2005;289:L842–L848
  52. Tokumaru S, Sayama K, Shirakata Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005;175:4662–4668
  53. Lee PH, Rudisill JA, Lin KH, et al. HB-107, a nonbacteriostatic fragment of the antimicrobial peptide cecropin B, accelerates murine wound repair. Wound Repair Regen. 2004;12:351–358
  54. Flad T, Bogumil R, Tolson J, et al. Detection of dermcidin-derived peptides in sweat by ProteinChip technology. J Immunol Methods. 2002;270:53–62
  55. Bardan A, Nizet V, Gallo RL. Antimicrobial peptides and the skin. Expert Opin Biol Ther. 2004;4:543–549
  56. Sorensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA, Ganz T. Differential regulation of beta-defensin expression in human skin by microbial stimuli. J Immunol. 2005;174:4870–4879
  57. Chen X, Niyonsaba F, Ushio H, et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci. 2005;40:123–132
  58. Lopez-Garcia B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol. 2005;125:108–115
  59. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414:454–457
  60. Lee PH, Ohtake T, Zaiou M, et al. Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. Proc Natl Acad Sci U S A. 2005;102:3750–3755
  61. Howell MD, Wollenberg A, Gallo RL, et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol. 2006;117:836–841
  62. Rieg S, Steffen H, Seeber S, et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol. 2005;174:8003–8010
  63. Mookherjee N, Brown KL, Bowdish DM, et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol. 2006;176:2455–2464
  64. McInturff JE, Wang SJ, Machleidt T, et al. Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against Propionibacterium acnes. J Invest Dermatol. 2005;125:256–263
  65. Mallbris L, Edstrom DW, Sundblad L, Granath F, Stahle M. UVB upregulates the antimicrobial protein hCAP18 mRNA in human skin. J Invest Dermatol. 2005;125:1072–1074
  66. Halliday GM. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res. 2005;571:107–120
  67. Carsberg CJ, Warenius HM, Friedmann PS. Ultraviolet radiation-induced melanogenesis in human melanocytes. Effects of modulating protein kinase C. J Cell Sci. 1994;107:2591–2597
  68. Burchill SA, Virden R, Thody AJ. Regulation of tyrosinase synthesis and its processing in the hair follicular melanocytes of the mouse during eumelanogenesis and phaeomelanogenesis. J Invest Dermatol. 1989;93:236–240
  69. Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology. 1996;137:1627–1633
  70. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. Faseb J. 2006;20:1561–1563
  71. Seiberg M, Paine C, Sharlow E, et al. Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol. 2000;115:162–167
  72. Suzuki I, Tada A, Ollmann MM, et al. Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha-melanotropin. J Invest Dermatol. 1997;108:838–842
  73. Park HY, Russakovsky V, Ohno S, Gilchrest BA. The beta isoform of protein kinase C stimulates human melanogenesis by activating tyrosinase in pigment cells. J Biol Chem. 1993;268:11742–11749
  74. Park HY, Russakovsky V, Ao Y, Fernandez E, Gilchrest BA. Alpha-melanocyte stimulating hormone-induced pigmentation is blocked by depletion of protein kinase C. Exp Cell Res. 1996;227:70–79
  75. Kwon BS, Haq AK, Pomerantz SH, Halaban R. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci U S A. 1987;84:7473–7477
  76. Park HY, Lee J, Gonzalez S, et al. Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. J Invest Dermatol. 2004;122:159–166
  77. Scott CP, Abel-Santos E, Wall M, Wahnon DC, Benkovic SJ. Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci U S A. 1999;96:13638–13643
  78. Kim H, Choi J, Cho JK, Kim SY, Lee YS. Solid-phase synthesis of kojic acid-tripeptides and their tyrosinase inhibitory activity, storage stability, and toxicity. Bioorg Med Chem Lett. 2004;14:2843–2846
  79. Noh JM, Kwak SY, Kim DH, Lee YS. Kojic acid-tripeptide amide as a new tyrosinase inhibitor. Biopolymers. 2007;88:300–307
  80. Rao S, Lang C, Levitan ES, Deitcher DL. Visualization of neuropeptide expression, transport, and exocytosis in Drosophila melanogaster. J Neurobiol. 2001;49:159–172
  81. Bonifacino JS, Glick BS. The mechanisms of vesicle budding and fusion. Cell. 2004;116:153–166
  82. Luger TA. Neuromediators–a crucial component of the skin immune system. J Dermatol Sci. 2002;30:87–93
  83. Fu FN, Lomneth RB, Cai S, Singh BR. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry. 1998;37:5267–5278
  84. Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24:303
  85. Molles BE, Tsigelny I, Nguyen PD, Gao SX, Sine SM, Taylor P. Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site. Biochemistry. 2002;41:7895–7906
  86. Allolio B, Arlt W. DHEA treatment: myth or reality?. Trends Endocrinol Metab. 2002;13:288–294
  87. Kim SK, Shin MS, Jung BK, et al. Effect of dehydroepiandrosterone on lipopolysaccharide-induced interleukin-6 production in DH82 cultured canine macrophage cells. J Reprod Immunol. 2006;70:71–81
  88. Mills SJ, Ashworth JJ, Gilliver SC, Hardman MJ, Ashcroft GS. The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors. J Invest Dermatol. 2005;125:1053–1062
  89. Navolotskaya EV, Zargarova TA, Lepikhova TN, et al. Study of immunosuppressive activity of a synthetic decapeptide corresponding to an ACTH-like sequence of human immunoglobulin G1. Biochemistry (Mosc). 1999;64:758–764
  90. Rocchi R, Biondi L, Cavaggion F, et al. Synthesis and biological activity of tuftsin and rigin derivatives containing monosaccharides or monosaccharide derivatives. Int J Pept Protein Res. 1987;29:262–275
  91. Yang Y, Marczak ED, Yokoo M, Usui H, Yoshikawa M. Isolation and antihypertensive effect of angiotensin I-converting enzyme (ACE) inhibitory peptides from spinach Rubisco. J Agric Food Chem. 2003;51:4897–4902
  92. Schwab A, Macerata R, Rogers W, Barton J, Skiles J, Khandwala A. Inhibition of angiotensin-converting enzyme by dipeptide analogs. Res Commun Chem Pathol Pharmacol. 1984;45:339–345
  93. Marczak ED, Usui H, Fujita H, et al. New antihypertensive peptides isolated from rapeseed. Peptides. 2003;24:791–798
  94. Ohtsuki K, Abe A, Mitsuzumi H, et al. Glucosyl hesperidin improves serum cholesterol composition and inhibits hypertrophy in vasculature. J Nutr Sci Vitaminol (Tokyo). 2003;49:447–450
  95. Hirata A, Murakami Y, Shoji M, Kadoma Y, Fujisawa S. Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res. 2005;25:3367–3374
  96. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9:165–169
  97. Partidos CD, Beignon AS, Brown F, Kramer E, Briand JP, Muller S. Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination. J Control Release. 2002;85:27–34
  98. Mitragotri S. Modeling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathways. J Control Release. 2003;86:69–92
  99. Lopes LB, Brophy CM, Furnish E, et al. Comparative study of the skin penetration of protein transduction domains and a conjugated peptide. Pharm Res. 2005;22:750–757
  100. Lopes LB, Collett JH, Bentley MV. Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur J Pharm Biopharm. 2005;60:25–30

PII: S0738-081X(09)00128-X

doi: 10.1016/j.clindermatol.2009.05.013

Clinics in Dermatology
Volume 27, Issue 5 , Pages 485-494 , September 2009

Article Tools